|Bid||17.48 x 500|
|Ask||17.51 x 500|
|Day's Range||17.07 - 17.72|
|52 Week Range||7.37 - 20.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.20|
CANTON, Mass., Dec. 12, 2017-- Collegium Pharmaceutical, Inc. today announced that management will be hosting investor meetings at the Guggenheim Securities 5 th Annual Boston Healthcare Conference on ...
Collegium rocketed to a 22-month high Tuesday after striking a deal with Depomed to commercialize its painkiller Nucynta.
The boost to U.S. stocks from tax-reform proved short-lived, with the Dow Jones Industrial Average finishing up less than 60 points, while the Nasdaq Composite and S&P 500 closed down 1.1% and 0.1%, respectively. The negative momentum has spilled over into Asia-Pacific markets with benchmark indices in Australia, Japan and Korea all in the red on Tuesday morning. In U.S. after-hours stock news: Collegium Pharmaceutical (COLL) jumped 9% after announcing that it has entered into a definitive agreement with Depomed to commercialize Nucynta tablets in the U.S. Depomed (DEPO) jumped 4.9% on the same agreement. Ascena Retail Group (ASNA) slumped 20% after the fashion retailer posted a 50% year--on-year drop in FY18 first quarter earnings and offered weak guidance for the upcoming quarter.
DepoMed Inc. announced Monday afternoon that it will allow Collegium Pharmaceutical Inc. to handle sales of its most lucrative product, the Nucynta line of painkillers, and slash its workforce. DepoMed ...
Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Immediately accretive, accelerates time to profitability Leverages Collegium’ ...
NEW YORK, Nov. 30, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Electronic ...
The FDA is working on ways to encourage the development of abuse-deterrent opioid pain relievers, and that's potentially bad news for this tiny biotech.
CANTON, Mass., Nov. 22, 2017-- Collegium Pharmaceutical, Inc. today announced that senior management will participate in a fireside chat at the 29 th Annual Piper Jaffray Healthcare Conference at 2:30pm ...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Collegium Pharmaceutical, Inc. a score of 29. Our analysis is based on comparing Collegium Pharmaceutical, Inc. with the following peers – Aoxing Pharmaceutical Company, Inc., Horizon Pharma plc, Agile Therapeutics, Inc. and Apricus Biosciences, Inc. (AOXG-US, HZNP-US, AGRX-US and APRI-US). Investment Outlook Collegium Pharmaceutical, Inc. has a ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Collegium Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
On a per-share basis, the Canton, Massachusetts-based company said it had a loss of 45 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Xtampza ® ER prescriptions grow by 49% in the third quarter FDA Approval of sNDA, including Comparative OxyContin Data Strong balance sheet provides cash runway into mid-2019 Conference call scheduled ...
NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Collegium Pharmaceutical, Inc. (NASDAQ: COLL ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:30 ...
Collegium Pharmaceutical Inc (NASDAQ:COLL) is a small-cap stock with a market capitalization of USD $295.37M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...